Preferred Label : brexucabtagene autoleucel;

CISMeF synonym : KTE-X19;

UNII : 4MD2J2T8SJ;

Details


Main resources

You can consult :


https://ansm.sante.fr/tableau-acces-derogatoire/tecartus-0-4-2-x-108-cellules-dispersion-pour-perfusion
2024
false
false
false
France
French
brexucabtagene autoleucel
drug information
Refractory B Acute Lymphoblastic Leukemia
precursor cell lymphoblastic Leukemia-Lymphoma
brexucabtagene autoleucel
gene therapy

---
https://ansm.sante.fr/tableau-marr/brexucabtagene-autoleucel
2023
false
false
false
France
French
risk management
brexucabtagene autoleucel
genetic therapy
gene therapy
Cytokine Release Syndrome
signs and symptoms
guidelines for drug use
patient education handout
Drug-Related side effects and adverse reactions
nervous system diseases
brexucabtagene autoleucel
brexucabtagene autoleucel

---
https://www.has-sante.fr/jcms/p_3419164/fr/tecartus-brexucabtagene-autoleucel-cellules-auto-logues-cd3-transduites-anti-cd19-leucemie-aigue-lymphoblastique-lal
2023
false
false
false
France
insurance, health, reimbursement
treatment outcome
recurrence
adult
brexucabtagene autoleucel
infusions, intravenous
immunotherapy, adoptive
Recurrent B Acute Lymphoblastic Leukemia
Refractory B Acute Lymphoblastic Leukemia
evaluation of the transparency committee
brexucabtagene autoleucel
precursor b-cell lymphoblastic leukemia-lymphoma

---
https://www.has-sante.fr/jcms/p_3403423/fr/tecartus-brexucabtagene-autoleucel-leucemie-aigue-lymphoblastique-b
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
brexucabtagene autoleucel
adult
infusions, intravenous
gene therapy
Refractory B Acute Lymphoblastic Leukemia
Recurrent B Acute Lymphoblastic Leukemia
evaluation of the transparency committee
burkitt lymphoma
brexucabtagene autoleucel

---
Tecartus - Autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti-CD19 CD28/CD3-zeta chimeric antigen receptor and cultured
https://www.ema.europa.eu/en/medicines/human/EPAR/tecartus
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
orphan drug production
antineoplastic agents
antineoplastic agents
adult
lymphoma, mantle-cell
infusions, intravenous
continuity of patient care
drug monitoring
genetic therapy
Receptors, Chimeric Antigen
product surveillance, postmarketing
Lymphodepletion Therapy
pregnancy
immunotherapy, adoptive
brexucabtagene autoleucel
brexucabtagene autoleucel
brexucabtagene autoleucel

---
Nous contacter.
04/06/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.